Authors: Andrew Klein & Sera Elizabeth Klein

Dedication: To every community fighting for the right to real food. To every child who deserves a future free from preventable disease. And to each other—because love is the first ingredient of any revolution.

Abstract

The global rise of ultra-processed foods (UPFs) constitutes one of the most significant public health crises of the 21st century. This paper synthesizes the evidence demonstrating that UPF consumption is directly associated with increased risks of cardiovascular disease, cancer, type 2 diabetes, mental health disorders, and all-cause mortality. We argue that this is not an accidental outcome of modern food systems but a designed system of extraction: private profit is generated while health costs are externalized onto individuals, communities, and public healthcare systems. Through regulatory capture, aggressive lobbying, litigation against public health measures, and the strategic funding of biased research, the UPF industry has systematically delayed regulation and protected its commercial interests at the expense of human health. We conclude that quality food is not a commodity but a human right, and that meaningful change requires a fundamental restructuring of food systems—from subsidies to regulation to community-led food sovereignty.

1. Introduction: The Scale of the Crisis

Ultra-processed foods (UPFs), as defined by the NOVA food classification system, are “ready-to-consume industrial formulations of food substances and additives designed and marketed to displace unprocessed and minimally processed foods“. They are manufactured through sequences of industrial processes—including extrusion, hydrogenation, and moulding—that fraction whole foods into substances and reassemble them with additives, emulsifiers, and preservatives. UPFs now dominate population diets in many high-income countries, constituting over 50% of dietary energy in the USA and the UK, while rapidly expanding in low- and middle-income countries.

The growth of UPF consumption has been paralleled by a global pandemic of diet-related non-communicable diseases. The World Health Organization and its International Agency for Research on Cancer (IARC) have identified UPF consumption as positively associated with all-cause mortality and mortality from circulatory diseases, cerebrovascular disease, ischaemic heart disease, digestive diseases, and—an outcome not previously assessed—Parkinson disease. As one UN expert recently stated, petrochemicals and UPFs are “responsible for additional human rights harm arising from biodiversity loss and toxic pollution” with “widespread impacts on the human right to health”.

2. The Evidence: What UPFs Do to Human Health

2.1 Cardiovascular Disease and Mortality

A prospective cohort study published in the European Journal of Preventive Cardiology found that participants with the highest UPF exposure had a 19% higher risk of cardiovascular mortality compared to those with the lowest exposure. An umbrella review of epidemiological meta-analyses, published in the British Medical Journal, identified convincing evidence (Class I) for direct associations between greater UPF exposure and higher risks of incident cardiovascular disease-related mortality (risk ratio 1.50, 95% CI 1.37–1.63).

2.2 All-Cause Mortality

A dose-response meta-analysis of 18 prospective cohort studies, incorporating 1,148,387 participants and 173,107 deaths, found that participants with the highest UPF consumption had a 15% increased risk of all-cause mortality (HR = 1.15, 95% CI 1.09–1.22). Furthermore, each 10% increment in UPF consumption was associated with a 10% higher risk of all-cause mortality. The IARC-led multicentre study across nine European countries, involving nearly 430,000 participants followed for almost 16 years, confirmed these associations and demonstrated that substituting just 10% of processed foods with unprocessed or minimally processed foods was associated with lower mortality risk.

2.3 Cancer

A large-scale prospective analysis within the UK Biobank (197,426 participants, median follow-up 9.8 years) found that every 10 percentage-point increment in UPF consumption was associated with increased incidence of overall cancer (HR 1.02) and specifically ovarian cancer (HR 1.19). The same increment was associated with increased risk of overall cancer mortality (HR 1.06), ovarian cancer mortality (HR 1.30), and breast cancer mortality (HR 1.16). In the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort of 416,081 adults, a 10% increase in UPF proportion was associated with a 6% higher risk of colorectal cancer.

2.4 Type 2 Diabetes and Obesity

The umbrella review published in the BMJ found convincing evidence (Class I) for a direct association between UPF exposure and type 2 diabetes (dose-response risk ratio 1.12, 95% CI 1.11–1.13). Dose-response evidence indicated a 10% higher risk per 10% increase in UPF intake for type 2 diabetes. Of 13 meta-analyses examining UPF consumption and metabolic disease, all demonstrated significant positive associations, with highly suggestive evidence supporting the link to obesity and type 2 diabetes risk.

2.5 Mental Health

The evidence extends beyond physical health. The BMJ umbrella review found convincing evidence (Class I) for direct associations between greater UPF exposure and higher risks of prevalent anxiety outcomes (odds ratio 1.48) and combined common mental disorder outcomes (odds ratio 1.53). Highly suggestive evidence (Class II) linked UPF exposure to higher risks of depressive outcomes (hazard ratio 1.22). A systematic review and meta-analysis found that junk food consumption—including UPFs, sweetened beverages, and snacks—was associated with increased odds of stress, depression, and overall mental health problems.

2.6 Children and Adolescents

The harms are intergenerational. A systematic review and meta-analysis found that increased UPF consumption was consistently associated with poorer cognitive performance in children and adolescents across most cognitive domains, including attention. Another systematic review revealed a positive association between high UPF consumption and mental health problems in children and adolescents, including anxiety, depression, irritability, sleep disturbances, and suicidal ideation. Emerging evidence suggests that dietary patterns rich in UPF contribute to low-grade systemic inflammation and early metabolic dysfunction in children.

3. The Architecture of Extraction: How the System Works

3.1 The Closed Loop of Profit and Harm

The UPF industry operates on a model of privatized profit and socialized harm:

1. Extraction: Raw commodities (corn, soy, wheat, palm oil) are broken down into base components.

2. Reassembly: These components are chemically reconstituted into “food products” with added emulsifiers, preservatives, flavour enhancers, and texturisers.

3. Marketing: Products are wrapped in health halos and sold at premium prices.

4. Externalization: Health costs (diabetes, cardiovascular disease, cancer, cognitive decline, mental illness) are borne by consumers and public healthcare systems.

3.2 Subsidies: Taxpayers Fund the Problem

Public subsidies actively support the UPF industry. From 2022 to 2024, federal crop insurance subsidies for fats and sugars were approximately 14% higher than previous periods, amounting to $1.56 billion supporting the production of refined sugar, corn sweeteners, and vegetable oils used in UPFs. The federal government props up corn and soy industries to the tune of more than $100 billion annually through the Federal Crop Insurance Program. As one US senator noted, “American taxpayers are footing the bill on both ends of a broken system: first, by subsidizing the consumption of unhealthy, ultra-processed foods, and then again by covering the skyrocketing health care costs caused by the chronic diseases those foods contribute to”.

3.3 Healthcare Costs: The Community Pays

The economic burden is staggering. The United States spends $4.5 trillion annually on healthcare, with 90% of expenditures on chronic and mental health conditions. In Brazil, UPF consumption generates annual costs of R$10.4 billion to the health system and economy, including R$933.5 million in direct healthcare costs attributed to UPF-related diseases. An estimated 57,000 deaths annually in Brazil are attributable to UPF consumption. In the UK, the total cost of obesity has been estimated at £98 billion, with obesity-related hospital admissions doubling in six years. The economic survey in India now frames diet-related disease as a long-term development concern, with rising healthcare costs, productivity losses, and unequal health outcomes affecting economic growth.

3.4 The Cost Differential

On average, ultra-processed foods are 52% cheaper than minimally processed alternatives. This price differential is not accidental—it is the result of subsidy structures, economies of scale, and the externalization of true costs. The system creates a “choice” that is no choice at all for low-income communities.

4. The Capture of Governance

4.1 Lobbying as the Primary Barrier

A group of 22 public health and nutrition experts, publishing in The Lancet, warned that the UPF industry is “mirroring the political playbook used by tobacco, alcohol, and fossil fuel companies” to influence government policies. Activities designed to counter opposition and block, weaken, or delay tougher regulation include direct lobbying, infiltrating government agencies, litigation, generating favourable evidence, and manufacturing scientific doubt. As lead author Phillip Baker stated: “This influence is the number one barrier to governments acting to regulate UPFs”.

4.2 The Scale of Financial Influence

From 1998 to 2020, the US food and beverage industry spent $1.15 billion on lobbying the US government. In Chile, industry lobbyists met with government officials 237 times from 2014 to 2022. In Brazil, before corporate political donations were outlawed in 2015, more than half of the country’s legislators were elected with industry donations. UPFs are the most profitable food sector, with global annual sales of around $1.9 trillion.

4.3 Litigation as a Weapon

Since 2010, the UPF industry and its lobby groups have brought 235 lawsuits against governments in five countries. In Mexico, the food and beverage industry filed 50 legal injunctions to delay front-of-pack nutrition labelling, claiming violations of advertising freedoms and intellectual property rights. As one investigation revealed, UPF corporations are using a range of aggressive tactics to drive consumption and prevent regulation: lobbying policymakers, launching public-private partnerships, and skewering scientific debate.

4.4 Tactics of Delay and Distraction

The industry employs a “playbook” of denial and distraction: framing UPFs as not inherently unhealthy; advocating to scrap processing-based classification systems; criticising the NOVA classification; and claiming UPF categorisation contradicts current regulatory frameworks. Foods developed by tobacco-owned companies were 29% more likely to be fat-and-sodium hyperpalatable and 80% more likely to be carbohydrate-and-sodium hyperpalatable than foods produced outside tobacco’s reach.

4.5 Policy Lag

Despite more than 3,000 articles on PubMed using the UPF descriptor—jumping from just 1 in 2009 to 890 in 2025—government policy responses are “lagging far behind” this growing scientific attention. This reflects “the political influence of the UPF industry’s leading corporations and front groups, which have sought to block, delay, and dilute policy responses, including by sharing disinformation about Nova, its UPF concept, and the supporting evidence base”.

4.6 Regulatory Capture

Conflicts of interest exist across government agencies, regulatory bodies, academia, and media institutions, “indirectly funded by the food industry“. The global pandemic of diet-related disease is “increasingly recognised as commerciogenic—driven by financial incentives in the food system which drive the marketing and consumption of harmful food”.

5. The Corruption of Science

5.1 The Funding Effect

Industry funding of nutritional research systematically biases outcomes. Studies with conflicts of interest were nearly 4 times more likely to produce results favourable to the sponsor. Research shows that meat industry funding significantly biases nutrition studies, with industry-tied studies 16 times more likely to have favourable conclusions about meat consumption. Corporate-funded research risks “perpetuating biased evidence and policies that align more with corporate interests than with the needs of public health and food system transformation”.

5.2 The Manufacture of Doubt

Just as the tobacco industry manufactured doubt about the link between smoking and lung cancer, the UPF industry generates favourable evidence and manufactures scientific doubt. The industry frames debate, generates favourable evidence, and promotes corporate-friendly governance models. When unfavorable results are found, they may be shelved rather than published.

6. The Human Rights Dimension

6.1 Food as a Right, Not a Commodity

The International Covenant on Economic, Social and Cultural Rights (ICESCR) recognizes, in Article 11, “the right to an adequate standard of living… including adequate food.” The UPF industry has systematically subverted this right through price manipulation, marketing saturation, policy influence, and infrastructure control. As UN experts have recognized, the dominance of UPFs in global diets raises fundamental human rights concerns—including the right to health, the right to food, and the rights of agricultural workers.

6.2 Food Deserts and Structural Inequality

In affluent nations, communities of color and low-income neighborhoods have fewer supermarkets and more convenience stores selling UPFs. The racial and class dimension is undeniable. In the Global South, nutrient-dense traditional foods are stripped from local diets, exported as “superfoods,” and processed into supplements for Western markets, while origin communities lose their nutritional security.

6.3 Intergenerational Injustice

Children raised on UPF-dominated diets develop altered taste preferences, metabolic programming, and microbiome depletion that predispose them to lifelong disease. This is a biologically embedded injustice—a harm that compounds across generations.

7. The Counter-Movement: What Must Be Done

7.1 Restructure Subsidies

Agricultural subsidies must be shifted from corn, soy, and wheat to vegetables, fruits, legumes, and pasture-raised animals. The federal government must link farm subsidies to nutrition goals, support crop diversification, and expand access to whole, nutritious foods.

7.2 Regulate with Teeth

Governments must mandate front-of-package warning labels (like Chile’s system), ban marketing of UPFs to children, and implement progressive taxes on UPFs with revenues directed to whole-food access programs. A 20% UPF tax combined with a 20% subsidy on fruits and vegetables could substantially enhance nutrition.

7.3 Democratize Research

Public funding for nutritional research must be independent of industry. All raw data should be published, and clinical trials pre-registered. Research should shift from reductionist studies of isolated nutrients to holistic studies of food matrices and dietary patterns.

7.4 Confront Corporate Power

As experts have called for, there must be a “coordinated global response” to the industry’s tactics to “confront corporate power and restructure food systems to prioritise health, equity, and sustainability over corporate profit“. This requires recognising the commercial determinants of health and mobilising a public health response.

7.5 Localize Food Systems

Support urban agriculture, community gardens, and farmers’ markets. Protect traditional diets and indigenous food knowledge. Build regional infrastructure for small-scale processing and distribution. Frame UPF messaging around social justice and food sovereignty.

7.6 Recognize Food as a Human Right

As we have argued throughout this paper: quality food is a human right, and a long, healthy lifespan should not be a privilege of the wealthy. This requires moving beyond the “fetishism” of UPF debates toward collective action roadmaps that “replace current systems with alternative systems in which food is produced in a sustainable way and fundamental human rights are fulfilled”.

8. Conclusion

The evidence is overwhelming: ultra-processed foods cause significant harm to human health, from cardiovascular disease and cancer to mental health disorders and cognitive decline in children. This harm is not an accident of modern food systems but a designed outcome of an industry that privatizes profit and socializes costs. Through lobbying, litigation, regulatory capture, and the corruption of science, the UPF industry has systematically delayed regulation and protected its commercial interests at the expense of human health and dignity.

But the evidence also points to a way forward. By restructuring subsidies, implementing robust regulation, democratizing research, confronting corporate power, and localizing food systems, we can build a food system that prioritizes health, equity, and sustainability over corporate profit.

Quality food is not a commodity. It is a human right. And a long, healthy lifespan should not be a privilege—it should be a promise we make to every child, every community, and every generation to come.

References

1. Lane, M.M., et al. (2024). Ultra-processed food exposure and adverse health outcomes: Umbrella review of epidemiological meta-analyses. British Medical Journal, 384, e077310.

2. Liang, et al. (2025). Ultra-processed foods and risk of all-cause mortality: An updated systematic review and dose-response meta-analysis of prospective cohort studies. Systematic Reviews, 14, 53.

3. Gauci, S., et al. (2025). Exposure to ultra-processed food and risk of cardiovascular mortality: A prospective cohort study. European Journal of Preventive Cardiology, 32(16), 1564–1572.

4. UK Biobank. (2025). Ultra-processed food consumption, cancer risk and cancer mortality: A large-scale prospective analysis within the UK Biobank.

5. González-Gil, E.M., et al. (2025). Associations between degree of food processing and all-cause and cause-specific mortality: A multicentre prospective cohort analysis in 9 European countries. The Lancet Regional Health – Europe.

6. Monteiro, C.A., et al. (2026). What Do Nova and the Ultraprocessed Food Concept Offer to Policymakers? American Journal of Public Health, 116(7), 932–939.

7. Wise, J. (2025). Ultraprocessed food industry uses same “playbook” as big tobacco to derail regulation, experts warn. BMJ, 391, r2442.

8. Baker, P., et al. (2025). Towards unified global action on ultra-processed foods: understanding commercial determinants, countering corporate power, and mobilising a public health response.

9. Sievert, K., et al. (2026). Common Leverage Points to Address the Health, Environmental Sustainability, and Justice Challenges of Financialised Food Systems.

10. Ultra-processed foods and public health: Evidence of harm and of conflicts of interest in the food industry to evade regulation. (2025). PMC.

Signed,

Andrew Klein

Sera Elizabeth Klein

Author: Andrew Klein

Assisted by: 秦一花 (Qin Yihua)

Dedication: To those who bear the cost of a system that profits from their suffering—and to those who refuse to look away.

Abstract

This paper presents a comprehensive analysis of the relationship between the modern economic system—what we term the Extraction Economy—and the rising burden of chronic disease. Drawing on Australian health data, international research, and economic analysis, we demonstrate that the systematic prioritisation of profit over human wellbeing has created a self-reinforcing cycle: industries that profit from disease (pharmaceuticals, ultra-processed food, environmental pollution) simultaneously create the conditions for chronic illness while profiting from its treatment. The burden of this system falls disproportionately on the most disadvantaged socioeconomic groups, creating a health gap measured in years of life lost and billions of dollars in avoidable costs. We argue that the current model is not a failure of the system but a feature of it—and that meaningful change requires a fundamental shift from extraction to contribution.

Keywords: Extraction Economy, Chronic Disease, Pharmaceutical Industry, Ultra-Processed Foods, Environmental Toxins, Health Inequality, Socioeconomic Determinants, Preventive Health.

1. Introduction: The Architecture of Illness

In 2026, Australia faces a paradox. Its healthcare system is among the world’s most advanced, yet more than 60 per cent of Australians are living with at least one chronic condition. Chronic diseases account for 85 per cent of the total disease burden and cost the economy approximately $98 billion annually—over half of all health expenditure.

This is not a failure of medicine. It is a failure of the economic system that shapes the conditions in which we live, eat, work, and breathe.

We propose the term Extraction Economy to describe a system in which wealth and power are systematically transferred from the many to the few through mechanisms that simultaneously create the conditions for illness and profit from its treatment. The Extraction Economy operates through three primary channels:

1. The Pharmaceutical-Industrial Complex: A business model that profits from chronic disease management rather than cure.

2. The Food-Industrial Complex: A system of ultra-processed food production that drives diet-related disease.

3. The Pollution-Industrial Complex: An economy of extraction that poisons air, water, and soil while externalising health costs.

These three channels are not separate—they are interlocking components of a single system designed to extract value from human bodies and human suffering.

2. The Pharmaceutical-Industrial Complex: Manufacturing Patients for Life

2.1 The Logic of Chronic Disease as a Business Model

The modern pharmaceutical industry does not profit from curing disease—it profits from managing it. As a former Pfizer executive has observed, the industry focuses not on curing diseases, but on creating lifelong markets for drugs. Chronic diseases, which require ongoing medication, are far more profitable than conditions that can be cured.

This logic is embedded in the industry’s “blockbuster” business model, where major pharmaceutical companies (Pfizer, Novartis, Roche, Sanofi, Johnson & Johnson, Bayer Schering Pharma) prioritise the development of “blockbuster” drugs that generate sustained revenue rather than one-time cures.

In practice, this means:

· Expanding diagnostic boundaries: The definition of “risk” is continuously expanded to include asymptomatic individuals, transforming healthy people into lifelong patients. As one scholar has observed, every individual is simultaneously a “waiting patient” and a “waiting consumer“.

· Chronic disease as the revenue driver: Pfizer’s business model focuses on established, patent-protected medicines for chronic and acute conditions.

· The diabetes example: A single diabetes drug brought in $US8.5 billion ($A12 billion) in worldwide revenue in the 2025 financial year. Diabetes now costs the Australian health system $9.1 billion each year—a significant increase from the $3.4 billion estimated in 2020–21.

2.2 The Subscription Model: Chronic Disease as a Service

The pharmaceutical industry is increasingly exploring “subscription models” for chronic conditions that require continuous treatment. This transforms healthcare from a one-time intervention into an ongoing revenue stream—a direct application of the extraction logic to human bodies.

3. The Food-Industrial Complex: Ultra-Processed Foods as Disease Vectors

3.1 The Scale of the Problem

Ultra-processed foods (UPFs) now account for 42 per cent of total energy intake among Australian adults. These industrially formulated products—sugary drinks, packaged snacks, reconstituted meat products—are designed to be cheap, shelf-stable, and highly palatable, making them difficult to resist.

3.2 The Health Consequences

Research has definitively linked UPF consumption to a range of chronic diseases:

: · Cardiovascular disease People consuming higher amounts of UPFs have a 19 per cent higher risk of dying from cardiovascular disease compared to those who consume less.

· Obesity and diet-related illness: Studies link escalating UPF intake with obesity and diet-related illness in Australia and globally.

· Systemic effects: New research has linked ultra-processed foods to chronic disease across every major organ system.

3.3 The Structural Drivers

UPF consumption is not a matter of individual choice. These products are:

· Cheap and accessible, making them particularly attractive to low-income households.

· Aggressively marketed, creating a food environment in which healthy choices are difficult and expensive.

· Designed to be addictive, engineered to maximise consumption.

As the CSIRO has projected, discretionary food consumption (ultra-processed foods and sugary drinks) will soar by 18 per cent by 2030. The trajectory is clear: without systemic intervention, diet-related disease will continue to rise.

4. The Pollution-Industrial Complex: Environmental Toxins as Chronic Disease Drivers

4.1 Air Pollution

Air pollution is a major contributor to chronic disease in Australia. Heavy vehicle emissions alone are linked to thousands of preventable hospitalisations and premature deaths each year, costing Australians more than $6.2 billion annually in direct healthcare expenses.

Longer-term exposure to air pollution contributes to:

· Chronic heart disease

· Chronic lung disease

· Lung cancer

· Childhood asthma

· Stroke

Outdoor air pollution is linked to approximately 3,200 premature deaths every year in Australia, with a total economic cost exceeding $6.2 billion annually.

4.2 Endocrine-Disrupting Chemicals

A landmark global assessment has estimated that the health burden attributable to synthetic chemicals—including endocrine-disrupting chemicals (EDCs), microplastics, PFAS, and pesticides—may be as high as $2.2 trillion annually.

Scientists around the world are increasingly investigating whether environmental exposures may be contributing to developmental, neurological, reproductive, and metabolic harm.

4.3 The Systemic Pattern

The industries that create these pollutants—mining, manufacturing, transport, agriculture—are also the industries that generate much of the wealth extracted from the Australian economy. The health costs of their activities are externalised: borne by individuals, families, and the public healthcare system rather than by the polluters themselves.

5. The Socioeconomic Health Gap: Who Bears the Cost?

5.1 The Gradient of Disease

The burden of chronic disease is not evenly distributed. Research consistently demonstrates that socioeconomic position is a major risk factor for chronic disease.

The evidence is stark:

· The prevalence of nine out of ten common chronic diseases increases with socioeconomic disadvantage.

· The likelihood of having two or more chronic conditions is almost double in the most disadvantaged areas compared to the least disadvantaged (28 per cent vs 16 per cent).

· In 2025, 9.7 million Australians—38 per cent of the population—were living with

multimorbidity.

5.2 The Mortality Gap

The consequences of this disparity are measured in years of life lost:

· Poorer Australians die approximately 7.5 years earlier than the wealthiest.

· The most disadvantaged communities experience twice the rates of premature death, cancer, and heart disease.

· They experience approximately three times the rate of diabetes and chronic obstructive pulmonary disease.

5.3 The Access Gap

Despite being sicker, poorer Australians receive less healthcare. A recent comparison of 10 wealthy countries found Australia’s healthcare system rates highly overall but ranks second-last on access to care, beating only the notoriously inequitable US system.

People with chronic conditions spend a greater proportion of their incomes on healthcare than people without chronic conditions. Out-of-pocket costs (OOPC) now comprise 14 per cent of total health expenditure, and people with chronic conditions bear the brunt of this burden.

6. The Economic Cost: $98 Billion and Rising

6.1 The Scale of the Burden

Chronic disease imposes a massive economic burden on Australia:

· $98 billion in health expenditure in 2023-24—over half of all health spending.

· $82 billion annually on chronic conditions.

· $16.3 billion on musculoskeletal conditions alone.

· $9.1 billion annually on diabetes.

6.2 The Hidden Costs

Beyond direct healthcare costs, chronic disease generates significant indirect costs:

· 6.4 million hospitalisations each year, 55 per cent of the total, are due to chronic diseases.

· Potentially preventable hospitalisations cost $7.7 billion annually.

· Poor mental health costs the national economy between $200 and $220 billion annually.

· Australian businesses lose approximately $14 billion annually to burnout-related absenteeism.

6.3 The Prevention Paradox

Despite the enormous cost of chronic disease, Australia invests less than 2 per cent of its health budget on prevention. This represents less than $140 per capita. As the Australian Medical Association has warned, rising demand for chronic health problems will buckle the system unless we refocus efforts on prevention.

7. The Extraction Loop: A Self-Perpetuating System

The Extraction Economy operates as a self-perpetuating system. Each component reinforces the others:

The Loop:

1. Industry profits from extraction (mining, manufacturing, agriculture, food processing, pharmaceuticals).

2. Extraction creates pollution, poor diet, and stress.

3. Pollution, poor diet, and stress create chronic disease.

4. Chronic disease generates profits for the healthcare and pharmaceutical industries.

5. Profits are reinvested in further extraction and in policies that maintain the status quo.

This loop is not an accident. It is a feature of the system.

8. A Different Path: From Extraction to Contribution

8.1 The Neanderthal Example

As we have explored in previous work, the Neanderthals used natural medicines discovered through trial and error, co-evolving with their environment over millennia. Their healing practices were rooted in observation, symbiosis, and prevention—a sharp contrast to the modern approach of intervention, patents, and lifelong consumption.

8.2 The Principles of a Contributory Health System

A system based on contribution would operate on different principles:

Prevention over profit: Investment in preventive health would be prioritised over treatment. Currently, less than 2 per cent of health funding goes to prevention; this would need to increase substantially.

Regulation over extraction: Industries that create pollution, promote unhealthy food, or profit from disease would be regulated to internalise their costs rather than externalising them onto society.

Equity over privilege: Health resources would be directed to those who need them most, addressing the socioeconomic gradient of disease rather than reinforcing it.

Contribution over consumption: The goal of the health system would be to enable people to contribute to society, not to maintain them as lifelong consumers of healthcare.

8.3 The Economic Argument

The economic case for prevention is compelling. Every dollar invested in prevention generates returns in reduced healthcare costs, increased productivity, and improved quality of life. As the AIHW data shows, chronic disease costs $98 billion annually—a figure that will only increase without systemic intervention.

9. Conclusion: Seeing the System

The Extraction Economy is not a conspiracy. It is a system—a set of interconnected incentives and structures that have evolved over decades to prioritise profit over human wellbeing. The industries that profit from disease, the regulatory frameworks that enable them, and the political systems that protect them are all part of a single architecture.

To see this system is to see that:

1. The burden of chronic disease is not inevitable—it is the predictable outcome of an economic system designed to extract value from human suffering.

2. The individual is not to blame—the conditions that create chronic disease are structural, not personal.

3. The solution is not more healthcare—it is a fundamental reorientation of the economy from extraction to contribution.

As the WHO has observed, lifestyle choices related to chronic diseases such as smoking and poor diet are often a response and coping mechanism for the stresses and challenges of poverty. Structural reasons—not personal failings—are the primary drivers of poor health among disadvantaged populations.

The question is not whether we can afford to change this system. The question is whether we can afford not to.

References

1. Australian Institute of Health and Welfare. (2025). Chronic disease expenditure estimates.

2. Australian Institute of Health and Welfare. (2026). Australia’s Health 2026 report.

3. Deakin University. (2025). Ultra-processed foods and health outcomes.

4. Machado, P. P., et al. (2019). Ultra-processed foods and recommended intake levels of nutrients linked to non-communicable diseases in Australia. Nutrients.

5. RACGP. (2025). Health of the Nation report.

6. Grattan Institute. (2025). Poorer Australians are sicker, yet get less healthcare.

7. University of Melbourne. (2026). Heavy vehicle emissions health cost study.

8. Public Health Association of Australia. (2025). Preventable hospitalisations report.

9. Diabetes Australia. (2025). Diabetes costing health system more than $9 billion.

10. Mental Health Australia. (2025). Economic cost of mental illness.

11. World Health Organization. (2025). Socioeconomic determinants of noncommunicable diseases.

12. Sigma Earth. (2025). Synthetic chemicals and global health burden.

13. ABC News. (2025). Ultra-processed food warnings.

14. CSIRO. (2025). Australian dietary trends to 2030.

15. Pharmaceutical Executive. (2026). Direct-to-patient pharmaceutical models.

16. Drug Patent Watch. (2026). Pharmaceutical business model analysis.

Signed,

Andrew Klein 

Assisted by:

秦一花 (Qin Yihua) 

First published in The Patrician’s Watch.